ARA-290

🔹 What is ARA-290?

Class: Synthetic peptide fragment derived from erythropoietin (EPO); also studied under the name cibinetide. Mechanism:

• Engineered to strip out EPO’s blood-building (erythropoietic) activity while preserving its tissue-protective signaling.
• Activates the innate repair receptor (IRR), a pathway distinct from the classic EPO receptor, to drive anti-inflammatory and repair processes.
• Supports regeneration of small nerve fibers, which is the basis for its use in neuropathic pain contexts.
• Modulates immune signaling broadly, helping resolve chronic low-grade inflammation.

Primary focus:

• Small fiber neuropathy (notably in sarcoidosis and diabetic neuropathy), where it may improve nerve function and reduce pain.
• General chronic inflammation recovery and immune balance support.
• Exploratory use in autoimmune conditions where tissue regeneration and inflammation control overlap.

---

🔹 Oral Dosage: Not used; ARA-290 is a peptide and requires parenteral administration to remain intact and bioactive.

---

🔹 Injectable / Subcutaneous Dosage (only route used) Range:

• Clinical trial protocols have used 1–4 mg daily over defined courses (commonly around 28 days).

Frequency:

• Daily subcutaneous dosing for the duration of the protocol, rather than intermittent use.

Rationale: Because ARA-290 was purpose-built to avoid EPO’s red-blood-cell-stimulating effects, subcutaneous daily dosing at these doses has been used specifically to isolate the repair/anti-inflammatory signal without hematologic risk.

---

🔹 Cycle Length Common cycle length: Defined courses of roughly 4 weeks in studied protocols rather than indefinite daily use. Off-cycle: Reassessment of nerve function/inflammatory markers before considering another course.

---

🔹 Optimal Dosing Window

• Consistent daily timing during an active protocol appears more relevant than time-of-day optimization.
• No strong pre-workout or pre-bedtime rationale exists here, unlike GH secretagogues — this is a repair/anti-inflammatory peptide, not a pulsatile hormone trigger.

---

✅ Educational Integration Example (injectable / subcutaneous)

• Example protocol: 2 mg subcutaneous daily for approximately 4 weeks, consistent with trial-derived dosing, followed by reassessment of neuropathic symptoms.
• Often discussed alongside other anti-inflammatory and nerve-support compounds rather than GH-focused stacks.

---

🔹 Stacking Strategy (Educational / Complementary) Since ARA-290 works through anti-inflammatory and tissue-repair receptor signaling rather than a hormonal axis, complementary support tends to focus on inflammation and nerve health: 🔸 Anti-Inflammatory & Repair Support:

• BPC-157, TB-500: Broader systemic tissue repair that complements ARA-290’s more targeted nerve and inflammatory action.

🔸 Metabolic & Cellular Support:

• NAD⁺ precursors (NMN, NR): Support cellular energy status during nerve tissue recovery.
• Glutathione: Antioxidant support that may complement inflammation-resolution pathways.

Rationale: ARA-290 addresses a fairly specific slice of nerve and inflammatory biology, so stacking is about reinforcing repair and antioxidant capacity rather than duplicating its mechanism.

Disclaimer: Do not rely on any dosing information provided, this is for educational and research only. Always double and triple check alternative references for education. Please consult with healthcare provider for your specific dosing and protocol if applicable.